Takeda has entered into a multi-year partnership with Iambic to use its AI models for drug discovery. The agreement is aimed at advancing small molecule programs. The total value of the deal may exceed $1.7 billion. The partnership is to support the development of medicines through artificial intelligence. Takeda thus gains access to advanced Iambic technologies. The agreement was announced as a strategic collaboration for long-term research.